We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Joseph Sabatino

Joseph J. Sabatino Jr., MD, PhD

Clinical Instructor, Department of Neurology and Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, California

Dr. Sabatino is a Clinical Instructor in the Department of Neurology and Weill Institute for Neurosciences at the University of California San Francisco. He received his MD/PhD from Emory University and completed his internship and residency training at Johns Hopkins Hospital. He became faculty after completing a combined clinical- and research-based fellowship in Multiple sclerosis/Neuroimmunology at the University of California San Francisco.

Dr. Sabatino’s clinical and research interests are in neuroimmunology, particularly on the role of T cells in multiple sclerosis (MS). His current research focuses on characterizing the CD8+ T cell response in MS as well as exploring potential T cell-B cell interactions in neuroinflammation. Dr. Sabatino has a number of publications on the role of T cells and B cells in MS and its animal models. He is the recipient of several research funding awards, including a K08 Career Development Award from the National Institutes of Health, a Career Transition Fellowship award from the National Multiple Sclerosis Society, and a Young Investigator Award from the Race to Erase MS.

Disclosures

Dr. Sabatino has no relevant disclosures.

Recent Contributions to PracticeUpdate:

  1. Ublituximab Use in Patients With Relapsing MS